468 related articles for article (PubMed ID: 32212583)
1. Comparison of
Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
[TBL] [Abstract][Full Text] [Related]
2. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.
Hadighi R; Boucher P; Khamesipour A; Meamar AR; Roy G; Ouellette M; Mohebali M
Parasitol Res; 2007 Oct; 101(5):1319-22. PubMed ID: 17610079
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of In vitro and In vivo Drug Efficacy Over Leishmania tropica: A Pilot Study.
Özbilgin A; Çavuş İ; Yıldırım A; Kaya T; Ertabaklar H
Turkiye Parazitol Derg; 2018 Mar; 42(1):11-19. PubMed ID: 29780014
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.
Utaile M; Kassahun A; Abebe T; Hailu A
Exp Parasitol; 2013 May; 134(1):68-75. PubMed ID: 23434530
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis.
Solomon M; Ollech A; Pavlotsky F; Barzilai A; Schwartz E; Baum S; Astman N
Acta Derm Venereol; 2024 Apr; 104():adv35089. PubMed ID: 38682801
[TBL] [Abstract][Full Text] [Related]
6. [Determination of Antimony Resistance Mechanism of Leishmania tropica Causing Cutaneous Leishmaniasis in Turkey].
Özbilgin A; Zeyrek FY; Güray MZ; Çulha G; Akyar I; Harman M; Özbel Y; Ertabaklar H; Çavuş İ; Gündüz C
Mikrobiyol Bul; 2020 Jul; 54(3):444-462. PubMed ID: 32755520
[TBL] [Abstract][Full Text] [Related]
7. Global distribution of treatment resistance gene markers for leishmaniasis.
Salari S; Bamorovat M; Sharifi I; Almani PGN
J Clin Lab Anal; 2022 Aug; 36(8):e24599. PubMed ID: 35808933
[TBL] [Abstract][Full Text] [Related]
8. Antimony susceptible
Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
[TBL] [Abstract][Full Text] [Related]
9. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Sensitivity of Cutaneous
Ginouvès M; Simon S; Nacher M; Demar M; Carme B; Couppié P; Prévot G
Am J Trop Med Hyg; 2017 May; 96(5):1143-1150. PubMed ID: 28167598
[TBL] [Abstract][Full Text] [Related]
11. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol.
Gonçalves G; Campos MP; Gonçalves AS; Medeiros LCS; Figueiredo FB
Parasit Vectors; 2021 Dec; 14(1):599. PubMed ID: 34886876
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate.
Ferreira BA; Coser EM; de la Roca S; Aoki JI; Branco N; Soares GHC; Lima MIS; Coelho AC
PLoS Negl Trop Dis; 2024 May; 18(5):e0012175. PubMed ID: 38768213
[TBL] [Abstract][Full Text] [Related]
13. Investigation of
Tunalı V; Harman M; Çavuş İ; Zorbozan O; Özbilgin A; Turgay N
Turkiye Parazitol Derg; 2022 May; 46(2):97-101. PubMed ID: 35604185
[TBL] [Abstract][Full Text] [Related]
14. Resistance of
Regli IB; Fernández OL; Martínez-Salazar B; Gómez MA; Saravia NG; Tacchini-Cottier F
Front Immunol; 2018; 9():3040. PubMed ID: 30622537
[No Abstract] [Full Text] [Related]
15. Involvement of tryparedoxin peroxidase (TryP) and trypanothione reductase (TryR) in antimony unresponsive of Leishmania tropica clinical isolates of Iran.
Nateghi-Rostami M; Tasbihi M; Darzi F
Acta Trop; 2022 Jun; 230():106392. PubMed ID: 35276060
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of visceral leishmaniasis in children].
Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Kumar D; Kulshrestha A; Singh R; Salotra P
Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
[TBL] [Abstract][Full Text] [Related]
18. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
Grogl M; Thomason TN; Franke ED
Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070
[TBL] [Abstract][Full Text] [Related]
20. Glucantime resistant Leishmania promastigotes are sensitive to pentostam.
Moreira ES; Guerra JB; Petrillo-Peixoto Mde L
Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
